Using the form, filter the technologies based on your search criteria. The results are based on the combined criteria.
The invention relates to protecting against Salmonella-type pathogens and more particularly, compositions and methods for immunizing against infection by typhoidal and non-typhoidal Salmonella serovars.
The invention consists of compounds for the treatment of parasitic diseases such as Trypanosomiasis and Leishmaniasis. Compounds are first-in-class, and selectively targeted towards pathogenic cells with nanomolar potency.
This is a novel seedless floating growth technique for synthesis of a variety of hybrid nanostructures on graphene, primarily for electronic and optoelectronic applications.
This method utilizes a novel solid catalyst made specifically for olefin epoxidation. The catalyst utilizes a base in order to allow hydrogen peroxide to be utilized as an oxidant. Further the system allows for a constant flow of feedstock to flow through the catalyst with minimal leaching of the metal from the catalyst allowing for a longer life of the catalyst.
Method for converting lignin biomass to aromatic compounds using a novel mesoporous acid catalyst.
This invention relates to a class of devices, the Radar Energy Absorbing Low Draw Vortex Generator (RAD-LDVG), which produce vortices over external or internal aerodynamic and/or hydrodynamic surfaces.
Most ZnO-nanostructure devices are fabricated using time-consuming nanomanipulation or one-by-one fabrication techniques, making them unattractive for large-scale production. Despite advantages in manufacturing cost and scalability, solutions-based processing has not produced high performing ZnO thin-film devices. This novel solutions-based process produces ZnO devices with shorter response times, lower device biases, and high light sensitivity.
This invention provides an improved method for producing a novel interfacing capillary device that is less costly and more durable than existing sheathless devices. This simplified production method does not require sample dilution, etching, or precision hand tools, and is automated and reproducible.
Regenerating and repairing individual organs and tissues for a single patient requires mass quantities of the patient’s own adult stem cells. Mass production of adult stem cells for therapeutic applications is highly limited due to the fact that adult stem cells have a limited shelf life when isolated from primary tissues of humans and animals. The act of removing adult stem cells from their original environment is traumatic and has the potential to induce changes or negative effects. Furthermore, the ability to grow adult stem cells in environments that mimic the original host tissue are limited. Adult stem cells lose “stemness” characteristics and the ability to divide and differentiate as adult stem cells are maintained and dissociated (passaged) from growth substrates, as is current practice.
This invention describes the first selective inhibitor of heat shock protein 90 kDa beta (Hsp90β). The invented inhibitor selectively binds to the N-terminus of Hsp90β and may be developed for the treatment of cancers. The inhibitor was developed based on the sequence alignment of the N-terminal ATP-binding domains of Hsp90α and Hsp90β complexed with a non-selective Hsp90 inhibitor, which revealed Hsp90β-specific residues that were key to exploit the selectivity of the new inhibitor.